Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Indocyanine Green

FDA-approved product (injectable, injection), marketed as Ic-Green, Indocyanine Green, Spy Agent Green Kit and 1 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Indocyanine Green
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

No approved indication recorded

ChEMBL records no approved indication for Indocyanine Green. Its therapeutic class is shown instead.

WHO therapeutic group
Other diagnostic agents
FDA pharmacologic class
Diagnostic Dye FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA41.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Indocyanine Green in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Indocyanine Green with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of the Association Between Genetic Load and Response to Anti-VEGF Therapy in AMD Patients

    NCT01644513 · start 2012-07

    Registered record
    Registry ID
    NCT01644513
    Conditions
    Age Related Macular Degeneration
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-07
    Completion
    2012-12
    Enrolment
    196

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAge Related Macular Degeneration
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Potential Use of Indocyanine Green as a Fluorescent Agent for Definition of Surgical Margins in Cancer

    NCT01884584 · start 2012-06

    Registered record
    Registry ID
    NCT01884584
    Conditions
    Malignant Neoplasm
    Interventions
    Indocyanine green (ICG)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-06
    Completion
    2015-01
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    InterventionIndocyanine green (ICG)
    PhasePhase 1
    Registry statusCompleted

  • A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer

    NCT01522937 · start 2009-10

    Registered record
    Registry ID
    NCT01522937
    Conditions
    Liver Cancer; Hepatocellular Cancer
    Interventions
    individualized Stereotactic Body Radiation Therapy (SBRT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-10
    Completion
    2015-11
    Enrolment
    94

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLiver Cancer; Hepatocellular Cancer
    Interventionindividualized Stereotactic Body Radiation Therapy (SBRT)
    PhasePhase 2
    Registry statusCompleted

  • Real-Time Image Guided Lymphatic Mapping and Nodal Targeting in Lung Cancer

    NCT00264602 · start 2009-02-18

    Registered record
    Registry ID
    NCT00264602
    Conditions
    Lung Cancer
    Interventions
    Near Infrared Imaging
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Active not recruiting
    Start
    2009-02-18
    Completion
    2029-12-01
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer
    InterventionNear Infrared Imaging
    PhasePhase 1
    Registry statusActive not recruiting

  • Vitrectomy for Branch Retinal Vein Occlusion

    NCT00685490 · start 1995-07

    Registered record
    Registry ID
    NCT00685490
    Conditions
    Vitrectomy
    Interventions
    Vitrectomy w/o ILM peeling for macular edema with BRVO
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    1995-07
    Completion
    2006-11
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVitrectomy
    InterventionVitrectomy w/o ILM peeling for macular edema with BRVO
    PhaseNot recorded
    Registry statusCompleted